67 results on '"Tanner, Caroline M."'
Search Results
2. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings
3. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia
4. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia
5. Excessive daytime sleepiness and topographic expansion of Lewy pathology
6. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
7. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
8. Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinsonʼs disease (EASE LID 3)
9. Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind
10. Lessons Learned From Past Gene-Environment Interaction Successes
11. National randomized controlled trial of virtual house calls for Parkinson disease
12. Biomarker‐driven phenotyping in Parkinsonʼs disease: A translational missing link in disease‐modifying clinical trials
13. Diffusion imaging of nigral alterations in early Parkinsonʼs disease with dopaminergic deficits
14. Traumatic brain injury in later life increases risk for Parkinson disease
15. Amantadine extended release for levodopa-induced dyskinesia in Parkinsonʼs disease (EASED Study)
16. Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease: A Randomized Clinical Trial
17. When brawn benefits brain: physical activity and Parkinson’s disease risk
18. Mendelian randomization of serum urate and parkinson disease progression
19. Peptidoglycan recognition protein genes and risk of Parkinsonʼs disease
20. The past, present, and future of telemedicine for Parkinsonʼs disease
21. A practical approach to remote longitudinal follow-up of Parkinsonʼs disease: The FOUND study
22. Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease
23. Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments
24. Relationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease
25. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
26. Alpha-synuclein: One key opens many locks
27. Caffeine Consumption and Risk of Dyskinesia in CALM-PD
28. Which Dyskinesia Scale Best Detects Treatment Response?
29. A Second Honeymoon for Parkinsonʼs Disease?
30. Genetic Modification of The Association of Paraquat And Parkinsonʼs Disease
31. Brain Organochlorines and Lewy Pathology: The Honolulu-Asia Aging Study
32. Comment on “Solvent exposures and Parkinson disease risk in twins”
33. Solvent exposures and parkinson disease risk in twins
34. Head injury, alpha-synuclein Rep1, and Parkinsonʼs disease
35. Predictors of time to requiring dopaminergic treatment in 2 Parkinsonʼs disease cohorts†
36. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinsonʼs disease
37. Comorbid cancer in Parkinsonʼs disease
38. Teaching program for the movement disorder society-sponsored revision of the Unified Parkinsonʼs Disease Rating Scale: (MDS-UPDRS)
39. Predictors of Parkin Mutations in Early-Onset Parkinson Disease: The Consortium on Risk for Early-Onset Parkinson Disease Study
40. Advances in environmental epidemiology
41. Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
42. Clinical Features in Early Parkinson Disease and Survival
43. Occupation and Risk of Parkinsonism: A Multicenter Case-Control Study
44. Bowel movement frequency in late-life and substantia nigra neuron density at death
45. Nicotine and Parkinsonʼs Disease: Implications for Therapy
46. Predictors of deterioration in health-related quality of life in Parkinsonʼs disease: Results from the DATATOP trial
47. Potential outcome measures and trial design issues for multiple system atrophy
48. Bowel movement frequency in late-life and incidental Lewy bodies
49. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy
50. Association of Olfactory Dysfunction With Incidental Lewy Bodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.